Herausforderungen in der Behandlung später antikörpermediierter Abstoßung

Farsad-Alexander Eskandary; Georg A. Böhmig

doi:10.1055/a-1169-8340

Dialyse aktuell, Table of Contents

Dialyse aktuell 2020; 24(08): 302-308
DOI: 10.1055/a-1169-8340

Schwerpunkt

Transplantation

Herausforderungen in der Behandlung später antikörpermediierter Abstoßung

Was sind die relevanten Aspekte bei Nierentransplantation?

Farsad-Alexander Eskandary

¹Klinische Abteilung für Nephrologie und Dialyse, Univ.-Klinik für Innere Medizin III, Medizinische Universität Wien, Wien (Österreich)

,

Georg A. Böhmig

¹Klinische Abteilung für Nephrologie und Dialyse, Univ.-Klinik für Innere Medizin III, Medizinische Universität Wien, Wien (Österreich)

› Author Affiliations

Abstract

ZUSAMMENFASSUNG

Derzeit gibt es keine Behandlung, die nachweislich in der späten und/oder chronischen antikörpervermittelten Abstoßung (ABMR) wirksam ist. Für Bortezomib und die kombinierte Anwendung von intravenösen Immunglobulinen (IVIG)/Rituximab haben doppelblinde randomisiert-kontrollierte Studien (RCTs) keine signifikante Wirkung auf deren Progression nachgewiesen. Der Antikörper Eculizumab konnte in einer kontrollierten Pilotstudie keine oder nur marginale klinische Wirkungen zeigen. Die größte Hoffnung stellen derzeit Therapien dar, welche die IL-6/IL-6R-Achse (IL-6R: Interleukin-6-Rezeptor) blockieren oder in der Lage sind, CD38-positive Zellen wie Plasma- und natürliche Killer-Zellen (NK-Zellen) zu depletieren.

Full Text

References

Literatur
1 Lefaucheur C, Loupy A. Antibody-Mediated Rejection of Solid-Organ Allografts. N Engl J Med 2018; 379: 2580-2582 doi:10.1056/NEJMc1813976.
2 Budde K, Dürr M. Any Progress in the Treatment of Antibody-Mediated Rejection?. J Am Soc Nephrol 2018; 29: 350-352 doi:10.1681/ASN.2017121296
3 Halloran PF, Famulski KS, Reeve J. Molecular assessment of disease states in kidney transplant biopsy samples. Nat Rev Nephrol 2016; 12: 534-548 doi:10.1038/nrneph.2016.85
4 Wiebe C, Nickerson PW. Human leukocyte antigen molecular mismatch to risk stratify kidney transplant recipients. Curr Opin Organ Transplant 2020; 25: 8-14 doi:10.1097/MOT.0000000000000714
5 Wasowska BA, Lee CY, Halushka MK, Baldwin WM 3rd. New concepts of complement in allorecognition and graft rejection. Cell Immunol 2007; 248: 18-30 doi:10.1016/j.cellimm.2007.04.009
6 Parkes MD, Halloran PF, Hidalgo LG. Evidence for CD16a-Mediated NK Cell Stimulation in Antibody-Mediated Kidney Transplant Rejection. Transplantation 2017; 101: e102-e111 doi:10.1097/TP.0000000000001586
7 Arnold ML, Kainz A, Hidalgo LG. et al Functional Fc gamma receptor gene polymorphisms and donor-specific antibody-triggered microcirculation inflammation. Am J Transplant 2018; 18: 2261-2273 doi:10.1111/ajt.14710
8 Loupy A, Haas M, Roufosse C. et al The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell- and antibody-mediated rejection. Am J Transplant 2020; 20: 2318-2331 doi:10.1111/ajt.15898
9 Halloran PF, Venner JM, Madill-Thomsen KS. et al Review: The transcripts associated with organ allograft rejection. Am J Transplant 2018; 18: 785-795 doi:10.1111/ajt.14600
10 Mengel M, Loupy A, Haas M. et al Banff 2019 Meeting Report: Molecular diagnostics in solid organ transplantation – Consensus for the Banff Human Organ Transplant (B-HOT) gene panel and open source multicenter validation. Am J Transplant 2020; 20: 2305-2317 doi:10.1111/ajt.16059
11 Reeve J, Böhmig GA, Eskandary F. et al Assessing rejection-related disease in kidney transplant biopsies based on archetypal analysis of molecular phenotypes. JCI Insight 2017; 2: e94197 doi:10.1172/jci.insight.94197
12 Aubert O, Loupy A, Hidalgo L. et al Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients. J Am Soc Nephrol 2017; 28: 1912-1923 doi:10.1681/ASN.2016070797
13 Eskandary F, Bond G, Kozakowski N. et al Diagnostic Contribution of Donor-Specific Antibody Characteristics to Uncover Late Silent Antibody-Mediated Rejection-Results of a Cross-Sectional Screening Study. Transplantation 2017; 101: 631-641 doi:10.1097/TP.0000000000001195
14 Wiebe C, Gibson IW, Blydt-Hansen TD. et al Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody. Am J Transplant 2015; 15: 2921-2930 doi:10.1111/ajt.13347
15 Kaplan B, Meier-Kriesche HU. Death after graft loss: an important late study endpoint in kidney transplantation. Am J Transplant 2002; 2: 970-974 doi:10.1034/j.1600-6143.2002.21015.x
16 Kikic Z, Kainz A, Kozakowski N. et al Capillary C4d and kidney allograft outcome in relation to morphologic lesions suggestive of antibody-mediated rejection. Clin J Am Soc Nephrol 2015; 10: 1435-1443 doi:10.2215/CJN.09901014
17 Loupy A, Lefaucheur C, Vernerey D. et al Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013; 369: 1215-1226 doi:10.1056/NEJMoa1302506
18 Sapir-Pichhadze R, Curran SP, John R. et al A systematic review of the role of C4d in the diagnosis of acute antibody-mediated rejection. Kidney Int 2014; 87: 182-194 doi:10.1038/ki.2014.166
19 Wan SS, Ying TD, Wyburn K. et al The Treatment of Antibody-Mediated Rejection in Kidney Transplantation: An Updated Systematic Review and Meta-Analysis. Transplantation 2018; 102: 557-568 doi:10.1097/TP.0000000000002049
20 Kulkarni S, Kirkiles-Smith NC, Deng YH. et al Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial. Am J Transplant 2017; 17: 682-691 doi:10.1111/ajt.14001
21 Moreso F, Crespo M, Ruiz JC. et al Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial. Am J Transplant 2018; 18: 927-935 doi:10.1111/ajt.1452
22 Eskandary F, Regele H, Baumann L. et al A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection. J Am Soc Nephrol 2018; 29: 591-605 doi:10.1681/ASN.2017070818
23 Kwun J, Burghuber C, Manook M. et al Humoral Compensation after Bortezomib Treatment of Allosensitized Recipients. J Am Soc Nephrol 2017; 28: 1991-1996 doi:10.1681/ASN.2016070727
24 Li J, Basler M, Alvaraz G. et al Immunoproteasome inhibition prevents chronic antibody-mediated allograft rejection in renal transplantation. Kidney Int 2018; 93: 670-680 doi:10.1016/j.kint.2017.09.023
25 Woodle ES, Shields AR, Ejaz NS. et al Prospective iterative trial of proteasome inhibitor-based desensitization. Am J Transplant 2015; 15: 101-118 doi:10.1111/ajt.13050
26 Jordan SC, Choi J, Kim I. et al Interleukin-6, A Cytokine Critical to Mediation of Inflammation, Autoimmunity and Allograft Rejection: Therapeutic Implications of IL-6 Receptor Blockade. Transplantation 2017; 101: 32-44 doi:10.1097/TP.0000000000001452
27 Eskandary F, Dürr M, Budde K. et al Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial. Trials 2019; 20: 37 doi:10.1186/s13063-018-3158-6
28 Palumbo A, Chanan-Khan A, Weisel K. et al Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med 2016; 375: 754-766 doi:10.1056/NEJMoa1606038
29 Doberer K, Kläger J, Gualdoni GA. et al CD38 Antibody Daratumumab for the Treatment of Chronic Active Antibody-mediated Kidney Allograft Rejection. Transplantation 2020 Mar 30. doi:10.1097/TP.0000000000003247. Online ahead of print
30 Kwun J, Matignon M, Manook M. et al Daratumumab in Sensitized Kidney Transplantation: Potentials and Limitations of Experimental and Clinical Use. J Am Soc Nephrol 2019; 30: 1206-1219 doi:10.1681/ASN.2018121254